Research programme: spinal cord injury therapies - Zealand Pharmaceuticals
Alternative Names: Gap junction modulatorsLatest Information Update: 21 May 2008
At a glance
- Originator Zealand Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 20 Apr 2008 Discontinued - Preclinical for Spinal cord injuries in Denmark (unspecified route)
- 26 Mar 2004 Preclinical trials in Spinal cord injuries in Denmark (unspecified route)